Cencora, Inc. (COR) stock

CORNYSEWholesale-Drugs, Proprietaries & Druggists' SundriesFiscal year ends September 30

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 15/3015% above fair value

$330.84+0.31 (+0.09%)

Close on Oct 30, 2026Market cap $63.13BP/E 24.6Yield 0.66%

Earnings

Cencora's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

Feb 3, 2027

Q1 FY2027 · estimated, before the open

Revenue, Q3 FY2026

$84.80B

+5.1% on a year earlier

Adjusted diluted EPS, Q3 FY2026

$4.48

$4.00 a year earlier

Latest guidance

Issued

Oct 21, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Cencora's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Adj. EPS	Source
Q1 FY2027ended Dec 31, 2026	Feb 3, 2027Expected	–	–	–	–	–
Q4 FY2026ended Sep 30, 2026	Oct 21, 2026before the open	–	–	–	–	Release
Q3 FY2026ended Jun 30, 2026	Aug 5, 2026before the open	$84.80B	+5.1%	$3.94	$4.48	Release
Q2 FY2026ended Mar 31, 2026	May 6, 2026before the open	$78.40B	+3.8%	$8.40	$4.75	Release
Q1 FY2026ended Dec 31, 2025	Feb 4, 2026before the open	$85.90B	+5.4%	$2.87	$4.08	Release
Q4 FY2025ended Sep 30, 2025	Nov 5, 2025before the open	$83.70B	+5.8%	-$1.75	$3.84	Release
Q3 FY2025ended Jun 30, 2025	Aug 6, 2025before the open	$80.70B	+8.8%	$3.52	$4.00	Release
Q2 FY2025ended Mar 31, 2025	May 7, 2025before the open	$75.50B	+10.4%	$3.68	$4.42	Release
Q1 FY2025ended Dec 31, 2024	Feb 5, 2025before the open	$81.50B	+12.7%	$2.50	$3.73	Release
Q4 FY2024ended Sep 30, 2024	Nov 6, 2024before the open	$79.10B	+14.8%	$0.02	$3.34	Release
Q3 FY2024ended Jun 30, 2024	Jul 31, 2024before the open	$74.20B	+10.9%	$2.42	$3.34	Release
Q2 FY2024ended Mar 31, 2024	May 1, 2024before the open	$68.40B	+7.7%	$2.09	$3.80	Release
Q1 FY2024ended Dec 31, 2023	Jan 31, 2024before the open	$72.30B	+15.1%	$2.98	$3.28	Release
Q4 FY2023ended Sep 30, 2023	Nov 2, 2023before the open	$68.90B	+12.6%	$1.72	$2.86	Release
Q3 FY2023ended Jun 30, 2023	Aug 2, 2023before the open	$66.90B	+11.3%	$2.35	$2.92	Release
Q2 FY2023ended Mar 31, 2023	May 2, 2023before the open	$63.50B	+10.1%	$2.13	$3.50	Release
Q1 FY2023ended Dec 31, 2022	Feb 1, 2023before the open	$62.80B	+5.4%	$2.33	$2.71	Release
Q4 FY2022ended Sep 30, 2022	Nov 3, 2022before the open	$61.20B	+3.9%	$1.40	$2.60	Release
Q3 FY2022ended Jun 30, 2022	Aug 3, 2022before the open	$60.10B	–	$1.92	$2.62	Release
Q2 FY2022ended Mar 31, 2022	May 4, 2022before the open	$57.70B	–	$2.59	$3.22	Release
Q1 FY2022ended Dec 31, 2021	Feb 2, 2022before the open	$59.60B	–	$2.13	$2.58	Release
Q4 FY2021ended Sep 30, 2021	Nov 4, 2021before the open	$58.90B	–	$2.08	$2.39	Release
Q3 FY2021ended Jun 30, 2021	Aug 4, 2021before the open	–	–	–	–	Release
Q2 FY2021ended Mar 31, 2021	May 5, 2021before the open	–	–	–	–	Release
Q1 FY2021ended Dec 31, 2020	Feb 4, 2021before the open	–	–	–	–	Release
Q4 FY2020ended Sep 30, 2020	Nov 5, 2020before the open	–	–	–	–	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Cencora's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Revenue	FY2026	+4% – +6%	+7% – +9%	Lowered	Aug 5, 2026
Revenuenon-GAAP	FY2026	+5% – +7%	–	New	Nov 5, 2025
Adjusted operating incomenon-GAAP	FY2026	+13% – +14%	+11.5% – +13.5%	Raised	Aug 5, 2026
adjusted diluted earnings per share (EPS)non-GAAP	FY2026	$17.90	–	New	Oct 21, 2026
Adjusted Diluted EPS Guidancenon-GAAP	FY2026	$17.75 – $17.95	$17.45 – $17.75	Raised	Aug 5, 2026
Adjusted free cash flownon-GAAP	FY2026	$3.00B	$3.00B	Reaffirmed	Aug 5, 2026
Capital expenditures	FY2026	$900.00M	$900.00M	Reaffirmed	Aug 5, 2026
Capital expendituresnon-GAAP	FY2026	$900.00M	–	New	Nov 5, 2025
Adjusted effective tax ratenon-GAAP	FY2026	20%	20%	Reaffirmed	Aug 5, 2026
Diluted weighted average shares outstanding	FY2026	194	195.5	Lowered	Aug 5, 2026
Diluted weighted average shares outstandingnon-GAAP	FY2026	194	–	New	Nov 5, 2025
Net interest expense	FY2026	$490.00M	$480.00M – $500.00M	Narrowed	Aug 5, 2026
Net interest expensenon-GAAP	FY2026	$315.00M – $335.00M	–	New	Nov 5, 2025

Guidance vs results

The last range Cencora gave before each report, against the figure it then reported. Full years add up the four quarters.

Period	Metric	Guidance	Actual	Result
FY2025	Adjusted diluted EPS	$15.85 – $16.00	$15.99Σ4Q	Within range
FY2025	Revenue growth	+9%	+9.32%Σ4Q	Above range

Guidance history

Every forecast Cencora put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Oct 21, 2026	adjusted diluted earnings per share (EPS)	FY2026	$17.90	New
Aug 5, 2026	Capital expenditures	FY2026	$900.00M	Reaffirmed
Aug 5, 2026	Adjusted Diluted EPS Guidance	FY2026	$17.75 – $17.95	Raised
Aug 5, 2026	Adjusted free cash flow	FY2026	$3.00B	Reaffirmed
Aug 5, 2026	Adjusted operating income	FY2026	+13% – +14%	Raised
Aug 5, 2026	U.S. Healthcare Solutions Segment	FY2026	+14.5% – +15.5%	Raised
Aug 5, 2026	International Healthcare Solutions Segment	FY2026	+9%	Lowered
Aug 5, 2026	Other	FY2026	+10%	Raised
Aug 5, 2026	Diluted weighted average shares outstanding	FY2026	194	Lowered
Aug 5, 2026	Adjusted effective tax rate	FY2026	20%	Reaffirmed
Aug 5, 2026	Net interest expense	FY2026	$490.00M	Narrowed
Aug 5, 2026	Revenue	FY2026	+4% – +6%	Lowered
Aug 5, 2026	U.S. Healthcare Solutions Segment	FY2026	+4% – +6%	Reaffirmed
Aug 5, 2026	International Healthcare Solutions Segment	FY2026	+8%	Raised
Aug 5, 2026	Other	FY2026	+6%	Lowered
Feb 4, 2026	Capital expenditures	FY2026	$900.00M	New
Feb 4, 2026	Adjusted diluted earnings per share	FY2026	$17.45 – $17.75	Reaffirmed
Feb 4, 2026	Adjusted free cash flow	FY2026	$3.00B	Reaffirmed
Feb 4, 2026	Adjusted operating income	FY2026	+11.5% – +13.5%	Raised
Feb 4, 2026	Diluted weighted average shares outstanding	FY2026	195.5	New
Feb 4, 2026	Adjusted effective tax rate	FY2026	20%	Lowered
Feb 4, 2026	Net interest expense	FY2026	$480.00M – $500.00M	New
Feb 4, 2026	Revenue	FY2026	+7% – +9%	New
Nov 5, 2025	Capital expenditures	FY2026	$900.00M	New
Nov 5, 2025	Adjusted diluted earnings per share	FY2026	$17.45 – $17.75	New
Nov 5, 2025	Adjusted free cash flow	FY2026	$3.00B	New
Nov 5, 2025	Adjusted operating income	FY2026	+8% – +10%	New
Nov 5, 2025	Diluted weighted average shares outstanding	FY2026	194	New
Nov 5, 2025	Adjusted effective tax rate	FY2026	20% – 21%	New
Nov 5, 2025	Net interest expense	FY2026	$315.00M – $335.00M	New
Nov 5, 2025	Revenue	FY2026	+5% – +7%	New
Aug 6, 2025	Adjusted diluted EPS	FY2025	$15.85 – $16.00	Raised
Aug 6, 2025	Adjusted consolidated operating income growth	FY2025	+15% – +16%	Raised
Aug 6, 2025	U.S. Healthcare Solutions segment operating income growth	FY2025	+20% – +21%	Raised
Aug 6, 2025	International Healthcare Solutions segment operating income decline	FY2025	-6%	Lowered
Aug 6, 2025	International Healthcare Solutions segment operating income decline (constant currency basis)	FY2025	-5%	Raised
Aug 6, 2025	Adjusted effective tax rate	FY2025	20.5% – 21%	New
Aug 6, 2025	Revenue growth	FY2025	+9%	Raised
Aug 6, 2025	U.S. Healthcare Solutions segment revenue growth	FY2025	+9% – +10%	Raised
Aug 6, 2025	International Healthcare Solutions segment revenue growth	FY2025	+6% – +7%	Lowered
Aug 6, 2025	International Healthcare Solutions segment revenue growth (constant currency basis)	FY2025	+7% – +8%	Raised
May 7, 2025	Adjusted diluted EPS	FY2025	$15.70 – $15.95	New
May 7, 2025	Adjusted consolidated operating income growth	FY2025	+13.5% – +15.5%	New
May 7, 2025	U.S. Healthcare Solutions segment operating income growth	FY2025	+17.5% – +19.5%	Raised
May 7, 2025	International Healthcare Solutions segment as reported operating income decline	FY2025	-4% – -1%	Lowered
May 7, 2025	Weighted average diluted shares outstanding	FY2025	195 – 195.5	New
May 7, 2025	International Healthcare Solutions segment revenue growth	FY2025	+3% – +4%	New
May 7, 2025	International Healthcare Solutions segment revenue growth (constant currency)	FY2025	+6% – +8%	Raised
Feb 5, 2025	Adjusted diluted EPS	FY2025	$15.25 – $15.55	Raised
Feb 5, 2025	Adjusted consolidated operating income growth	FY2025	+11.5% – +13.5%	Raised
Feb 5, 2025	Net interest expense	FY2025	$290.00M – $310.00M	New
Feb 5, 2025	Revenue growth	FY2025	+8% – +10%	New
Nov 6, 2024	Capital expenditures	FY2025	$600.00M	New
Nov 6, 2024	adjusted diluted EPS growth	FY2025	+8% – +10%	New
Nov 6, 2024	Adjusted diluted earnings per share	FY2025	$14.80 – $15.10	New
Nov 6, 2024	Adjusted free cash flow	FY2025	$2.00B – $3.00B	New
Nov 6, 2024	adjusted operating income growth	FY2025	+5% – +6.5%	New
Nov 6, 2024	Weighted average diluted shares outstanding	FY2025	196	New
Nov 6, 2024	Adjusted effective tax rate	FY2025	21%	New
Nov 6, 2024	Interest expense	FY2025	$150.00M – $170.00M	New
Nov 6, 2024	Revenue growth	FY2025	+7% – +9%	New
Jul 31, 2024	Adjusted diluted earnings per share	FY2024	$13.55 – $13.65	Raised
Jul 31, 2024	Adjusted free cash flow	FY2024	$2.50B – $3.00B	Raised
Jul 31, 2024	Adjusted consolidated operating income growth	FY2024	+10% – +11%	Raised
Jul 31, 2024	Net interest expense	FY2024	$170.00M – $190.00M	Lowered
Jul 31, 2024	Revenue growth	FY2024	+12%	Raised
May 1, 2024	Adjusted diluted earnings per share	FY2024	$13.30 – $13.50	Raised
May 1, 2024	Adjusted consolidated operating income growth	FY2024	+9% – +11%	Raised
May 1, 2024	Weighted average diluted shares outstanding	FY2024	201 – 202	Raised
May 1, 2024	Adjusted effective tax rate	FY2024	21%	Raised
May 1, 2024	International Healthcare Solutions segment revenue growth	FY2024	+4% – +7%	Lowered
Jan 31, 2024	Adjusted diluted earnings per share	FY2024	$13.25 – $13.50	Raised
Jan 31, 2024	Adjusted consolidated operating income growth	FY2024	+8% – +10%	Raised
Jan 31, 2024	Net interest expense	FY2024	$185.00M – $215.00M	Lowered
Jan 31, 2024	Revenue growth	FY2024	+10% – +12%	Raised
Nov 2, 2023	Capital expenditures	FY2024	$500.00M	New
Nov 2, 2023	Adjusted diluted earnings per share	FY2024	$12.70 – $13.00	New
Nov 2, 2023	Adjusted free cash flow	FY2024	$2.50B	New
Nov 2, 2023	Adjusted operating income growth	FY2024	+4% – +6%	New
Nov 2, 2023	Weighted average diluted shares outstanding	FY2024	200 – 202	New
Nov 2, 2023	Adjusted effective tax rate	FY2024	20% – 21%	New
Nov 2, 2023	Interest expense	FY2024	$210.00M – $230.00M	New
Nov 2, 2023	Revenue growth	FY2024	+7% – +10%	New
Aug 2, 2023	Adjusted Diluted Earnings Per Share	FY2023	$11.85 – $11.95	Raised
Aug 2, 2023	Adjusted free cash flow	FY2023	$2.00B	Reaffirmed
Aug 2, 2023	Adjusted consolidated operating income growth	FY2023	+3% – +4%	Raised
Aug 2, 2023	Revenue growth	FY2023	+8%	Raised
May 2, 2023	Adjusted Diluted Earnings Per Share	FY2023	$11.70 – $11.90	Raised
May 2, 2023	Adjusted consolidated operating income growth	FY2023	+2% – +4%	Lowered
May 2, 2023	Weighted average diluted shares	FY2023	205	Lowered
May 2, 2023	Revenue growth	FY2023	+6% – +8%	Raised
Feb 1, 2023	Adjusted Diluted Earnings Per Share	FY2023	$11.50 – $11.75	Raised
Feb 1, 2023	adjusted consolidated operating income growth	FY2023	+4% – +6%	Raised
Feb 1, 2023	Weighted average diluted shares	FY2023	206	Lowered
Nov 3, 2022	Capital expenditures	FY2023	$500.00M	New
Nov 3, 2022	Adjusted diluted earnings per share	FY2023	$11.30 – $11.60	New
Nov 3, 2022	Adjusted free cash flow	FY2023	$2.00B	New
Nov 3, 2022	Adjusted operating income growth	FY2023	0% – +3%	New
Nov 3, 2022	Weighted average diluted shares	FY2023	207 – 209	New
Nov 3, 2022	Adjusted effective tax rate	FY2023	20% – 21%	New
Nov 3, 2022	Revenue growth	FY2023	+5% – +7%	New
Aug 3, 2022	Adjusted Diluted Earnings Per Share	FY2022	$10.90 – $11.10	Raised
Aug 3, 2022	Adjusted free cash flow	FY2022	$2.30B – $2.50B	Raised
Aug 3, 2022	U.S. Healthcare Solutions operating income	FY2022	$2.44B – $2.48B	Raised
Aug 3, 2022	Weighted average diluted shares	FY2022	211 – 211.5	Lowered
May 4, 2022	Adjusted Diluted Earnings Per Share	FY2022	$10.80 – $11.05	Raised
May 4, 2022	U.S. Healthcare Solutions operating income	FY2022	$2.42B – $2.48B	Raised
Feb 2, 2022	Adjusted Diluted Earnings Per Share	FY2022	$10.60 – $10.90	Raised
Feb 2, 2022	U.S. Healthcare Solutions operating income	FY2022	$2.38B – $2.45B	Raised
Feb 2, 2022	Interest expense	FY2022	$210.00M – $215.00M	New
Nov 4, 2021	Capital expenditures	FY2022	$500.00M	New
Nov 4, 2021	Adjusted diluted earnings per share	FY2022	$10.50 – $10.80	New
Nov 4, 2021	Adjusted free cash flow	FY2022	$2.00B – $2.50B	New
Nov 4, 2021	International Healthcare solutions segment operating income	FY2022	$685.00M – $715.00M	Lowered
Nov 4, 2021	U.S. Healthcare Solutions segment operating income	FY2022	$2.33B – $2.40B	New
Nov 4, 2021	Weighted average diluted shares	FY2022	212	New
Nov 4, 2021	Adjusted effective tax rate	FY2022	21% – 22%	New
Nov 4, 2021	U.S. Healthcare Solutions revenue	FY2022	$207.00B – $212.00B	New
Nov 4, 2021	International Healthcare Solutions revenue	FY2022	$26.00B – $27.00B	Lowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.